TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Bridgebio Pharma
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis significantly reduces all-cause mortality in variant ATTR-CM populations, with a 69% risk reduction in mortality for patients with the V142I genetic variant.

Insights
BACpB   neutral

Serving as joint sponsor and coordinator for the IPO, indicating a standard professional engagement


BBIO   positive

Demonstrated significant clinical benefits of acoramidis in reducing mortality for a high-risk patient population, presenting promising research results with potential meaningful impact on patient outcomes